Our Story

Bringing the academic and industrial spheres together

The Bioprojet company was founded in 1982 under the impetus of Jeanne-Marie Lecomte and Jean-Charles Schwartz, doctors of pharmacy and sciences. From very different backgrounds, Jeanne-Marie Lecomte made her career in the pharmaceutical industry, whereas Jean-Charles Schwartz continued down the university pathway. They decided to bring together academic research and industrial pharmaceutical development, an uncommon practice at that time. With Bioprojet, they are following an objective based on novel fundamental research work in order to design and develop drugs destined to be forerunners in new therapeutic groups. To achieve this ambition, Bioprojet has partnered with Inserm, where Jean-Charles Schwartz leads a research unit, and with various Medicinal Chemistry university laboratories.

Today, Bioprojet is divided into two entities, bringing together 87 employees in charge of drug development and marketing:

  • Bioprojet PHARMA, created in 1992, brings together 42 employees in charge of drug development and marketing.
  • Bioprojet BIOTECH, created in 2001, brings together 45 employees managing the Group’s R&D. There are four units: biochemistry / molecular biology, therapeutic chemistry, pharmacology and pharmacokinetics.

First worldwide success

The first joint research project between Bioprojet and Inserm covers neurotransmitters, endogenous opioids, the discovery of a new enzyme responsible for their inactivation, and in 1993 it led to the launch of Tiorfan®/Hidrasec®, the first pure intestinal anti-secretory drug for the treatment of diarrhoea.

With a mechanism of action affecting the core water and electrolyte regulation system of the digestive tract, the drug met with clear worldwide success in 2000 with the marketing of its paediatric version. Distributed in 70 countries in Europe, Africa, Asia and Latin America, racecadotril (scientific name) is used by over 10 million patients each year. To date, more than one hundred million patients have already benefited from it, whereas several development program are under way, including an oral suspension.

A fundamental discovery related to another histamine receptor resulted in the development of pitolisant. Marketed under the name Wakix®, the drug is indicated in adults for the treatment of narcolepsy, with or without cataplexy. Wakix® has been authorized for registration in the 28 European Union countries since 2016, and should be registered with the American FDA.

The Group's ongoing development

In 2001, Bioprojet acquired the GSK research centre in Saint-Grégoire near Rennes, housed its researchers as well as local researchers, and reorganized it. The objective was to create new molecules and to conduct the preclinical development of these candidate drugs. A thousand molecules are designed and studied there each year.

The Group is also continuing its development by purchasing marketing licenses or international rights for drugs, the active substances of which fall into their areas of expertise: Remodulin® in 2006, Clastoban® in 2012 and Anapen® in 2013. Bioprojet is continuing to develop them to create new formulations, combinations and to extend their indications.

In 2013 Bioprojet acquired the UK company Lincoln, owner of the worldwide rights for Anapen®.

Finally, since the early 2000s, the Group has been setting several subsidiaries up on an international scale. Bioprojet is currently operating in nine countries (France, Benelux, Italy, United Kingdom, Germany, Spain, and Tunisia). The Group intends to reinforce its targeted research strategy model and to increase its international importance, either directly or through partnerships.

Our values

The Bioprojet Collaborators follow a path drawn by the Founders and are guided in their…

Know more

The 2017 Francophone Allergology Congress

Again this year, Bioprojet will be taking part in the Francophone Allergology Congress held in…

Know more